<table id="table20" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 20: Summary of the Effect of Coadministered Drugs on Posaconazole in Healthy Volunteers</caption>
<col align="left" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<thead>
<tr stylecode="Botrule">
<th align="center" rowspan="2" stylecode="Lrule Rrule" valign="bottom">Coadministered Drug (Postulated Mechanism of Interaction)</th>
<th align="center" rowspan="2" stylecode="Rrule" valign="bottom">Coadministered Drug Dose/Schedule</th>
<th align="center" rowspan="2" stylecode="Rrule" valign="bottom">Posaconazole Dose/Schedule</th>
<th align="center" colspan="2" stylecode="Rrule" valign="bottom">Effect on Bioavailability of Posaconazole</th>
</tr>
<tr>
<th align="center" stylecode="Rrule" valign="bottom">Change in Mean<br/>C<sub>max</sub>
<br/>(ratio estimate<footnote id="t19f1">Ratio Estimate is the ratio of coadministered drug plus posaconazole to posaconazole alone for C<sub>max</sub> or AUC.</footnote>; 90% CI of the ratio estimate)</th>
<th align="center" stylecode="Rrule" valign="bottom">Change in Mean AUC<br/>(ratio estimate<footnoteref idref="t19f1"></footnoteref>; 90% CI of the ratio estimate)</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Efavirenz<br/>(UDP-G Induction)</td>
<td stylecode="Rrule">400 mg QD × 10 and 20 days</td>
<td stylecode="Rrule">400 mg (oral suspension) BID × 10 and 20 days</td>
<td stylecode="Rrule">↓45%<br/>(0.55; 0.47-0.66)</td>
<td stylecode="Rrule">↓ 50%<br/>(0.50; 0.43-0.60)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fosamprenavir (unknown mechanism)</td>
<td stylecode="Rrule">700 mg BID × 10 days</td>
<td stylecode="Rrule">200 mg QD on the 1<sup>st</sup> day, 200 mg BID on the 2<sup>nd</sup> day, then 400 mg BID × 8 Days</td>
<td stylecode="Rrule">↓21%<br/>0.79 (0.71-0.89)</td>
<td stylecode="Rrule">↓23%<br/>0.77 (0.68-0.87)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifabutin<br/>(UDP-G Induction)</td>
<td stylecode="Rrule">300 mg QD × 17 days</td>
<td stylecode="Rrule">200 mg (tablets) QD × 10 days<footnote id="t19f2">The tablet refers to a non-commercial tablet formulation without polymer.</footnote>
</td>
<td stylecode="Rrule">↓ 43%<br/>(0.57; 0.43-0.75)</td>
<td stylecode="Rrule">↓ 49%<br/>(0.51; 0.37-0.71)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenytoin<br/>(UDP-G Induction)</td>
<td stylecode="Rrule">200 mg QD × 10 days</td>
<td stylecode="Rrule">200 mg (tablets) QD × 10 days<footnoteref idref="t19f2"></footnoteref>
</td>
<td stylecode="Rrule">↓ 41%<br/>(0.59; 0.44-0.79)</td>
<td stylecode="Rrule">↓ 50%<br/>(0.50; 0.36-0.71)</td>
</tr>
</tbody>
</table>